Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) shares saw an uptick in trading volume on Friday . 6,529,447 shares were traded during trading, an increase of 689% from the previous session’s volume of 827,717 shares.The stock last traded at $3.14 and had previously closed at $2.77.

Separately, Maxim Group decreased their price target on shares of Adamis Pharmaceuticals Corp. from $17.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, July 21st.

The stock’s market capitalization is $72.47 million. The company has a 50 day moving average of $2.87 and a 200-day moving average of $5.24.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.